SCHEMBL2163493

SCHEMBL2163493

CCC(Cl)Oc1cc2nnnc(Nc3ccc(Cl)cc3)c2cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.54
FLT1 P17948 1/20 0.54
TNF P01375 1/20 0.46
EGFR P00533 8/20 0.44
HDAC3 O15379 4/20 0.43
HDAC4 P56524 4/20 0.43
HDAC1 Q13547 4/20 0.43
HDAC7 Q8WUI4 4/20 0.43
HDAC2 Q92769 4/20 0.43
HDAC10 Q969S8 4/20 0.43
HDAC11 Q96DB2 4/20 0.43
HDAC8 Q9BY41 4/20 0.43
HDAC6 Q9UBN7 4/20 0.43
HDAC9 Q9UKV0 4/20 0.43
HDAC5 Q9UQL6 4/20 0.43
CCR4 P51679 3/20 0.43
FBP1 P09467 2/20 0.42
AURKA O14965 1/20 0.42
ERBB2 P04626 1/20 0.42
INSR P06213 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163565 0.92 SLC2A1 (0.50) KDRFLT1EGFRERBB2LCK
SCHEMBL2164524 0.91 EGFR (0.53) KDRFLT1EGFRHDAC3HDAC4
SCHEMBL2163645 0.90 EGFR (0.51) KDRFLT1EGFRFBP1AURKA
SCHEMBL2163601 0.90 EGFR (0.42) KDRFLT1EGFRFBP1AURKA
SCHEMBL2163097 0.90 KDR (0.48) KDRFLT1EGFRFBP1AURKA
SCHEMBL2164226 0.89 EGFR (0.58) KDREGFRFBP1AURKAERBB2
SCHEMBL2165591 0.89 EGFR (0.56) KDRTNFEGFRHDAC3HDAC4
SCHEMBL2163629 0.88 EGFR (0.49) KDRFLT1EGFRERBB2EPHB4
SCHEMBL2163900 0.86 EGFR (0.43) KDRFLT1EGFRLCKABL1
SCHEMBL2164278 0.85 KDR (0.45) KDREGFRFBP1AURKAERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US claimed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 KDR 1/4885FLT1 2/4885TNF 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.